Form 8-K



Washington, D.C. 20549




Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2008


Seattle Genetics, Inc.

(Exact name of Registrant as specified in its charter)



Delaware   0-32405   91-1874389

(State or other jurisdiction of

incorporation or organization)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

21823 30th Drive SE

Bothell, Washington 98021

(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 7.01 Regulation FD Disclosure.

On January 14, 2008, the Company issued a press release announcing its intention to conduct an underwritten public offering. A copy of the press release is attached as Exhibit 99.1 to this report.

In addition, the Company reported that it expects net cash used in operating activities in 2008 to range from $55 million to $65 million. This statement reflects the Company’s current views about future events and is subject to significant risks and uncertainties, including those discussed below and those described more fully in other reports filed by the Company with the SEC. Because this statement reflects its current expectations concerning future events, the Company’s actual results could differ materially. The factors that could cause actual results to differ from its expectations include, but are not limited to, the timing of manufacturing campaigns, accrual of patients to clinical trials, collaborative activities, the cost of filing and enforcing patent claims and other intellectual property rights, competing technological and market developments and the progress of its collaborators.

The information in this Current Report on Form 8-K under the heading Item 7.01, “Regulation FD Disclosure,” including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


99.1    Press release dated January 14, 2008


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 14, 2008     By:   /s/ Clay B. Siegall
        Clay B. Siegall
        President and Chief Executive Officer



Exhibit No.   


99.1    Press release dated January 14, 2008